Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
melanoma
Biotech
Immatics leaps into phase 3 on strength of early-stage PFS data
Immatics is starting a pivotal trial of its melanoma cell therapy in light of the response and PFS results seen in a phase 1b study.
Nick Paul Taylor
Oct 10, 2024 8:49am
Black Diamond, Ideaya mull registrational trials for cancer meds
Sep 23, 2024 12:18pm
BioNTech, Regeneron rack up response rate win for cancer vaccine
Jul 30, 2024 6:45am
Merck halts phase 3 melanoma TIGIT trial due to discontinuations
May 13, 2024 8:39am
AACR: Cancer vaccines get a reintroduction
Apr 10, 2024 4:30am
Ultimovacs' cancer vaccine flunks another checkpoint combo test
Mar 7, 2024 6:14am
